Treatment With Tocilizumab in a Patient With COVID-19

Hamideh  Abbaspour Kasgari; Hamidreza  Samaee; Shahriar   Alian Samakkhah; Parisa   Moradimajd

doi:10.18502/pbr.v6i(S2).5662

Hamideh Abbaspour Kasgari
Hamidreza Samaee
Shahriar Alian Samakkhah
Parisa Moradimajd

DOI: https://doi.org/10.18502/pbr.v6i(S2).5662

Keywords: Coronavirus, Tocilizumab, Pandemic, COVID-19

Abstract

In late December 2019, a global outbreak (pandemic) of the coronavirus was reported, which WHO named 2019-nCoV. The virus is now spreading rapidly and has affected many
countries, including Iran. There is no definitive and effective treatment for this virus yet. This report aimed to define the effect of Tocilizumab in patient with COVID-19. This case report is
about a 52-year-old man with COVID-19 that has been treated with tocilizumab. The reported patient had an acceptable improvement in oxygen saturation but no significant change in
lung CT scan. After 3 days treatment patient with Tocilizumab, extensive bilateral lungs involvement still exist but SPO2 level iimprovement up to 90%. According to the results, this
drug had a positive impact on oxygen saturation. However, we cannot be certain whether this drug positively affected the patient’s coronavirus disease.